Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases

British Journal of Surgery

Volumn 102, Issue 10, 2015, Pages 1175-1183

  Brudvik, K W ^a   Kopetz, S E ^a   Li, L ^a   Conrad, C ^a   Aloia, T A ^a   Vauthey, J N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

COLON RESECTION; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; HEALTH; HUMAN; META ANALYSIS; METASTASIS; MUTATION; SECONDARY; SURVIVAL RATE;

COLECTOMY; COLORECTAL NEOPLASMS; DNA, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GLOBAL HEALTH; HUMANS; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL RATE;

EID: 84939251514     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9870     Document Type: Review

References (55)

1. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, et-al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011; 29: 1083-1090.
2. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH,. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.
3. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, et-al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189: 291-299.
4. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG,. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247: 125-135.
5. Nathan H, de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, et-al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg 2010; 210: 755-764, 764-766.
6. Reissfelder C, Rahbari NN, Koch M, Ulrich A, Pfeilschifter I, Waltert A, et-al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol 2009; 16: 3279-3288.
7. Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, et-al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 2007; 246: 183-191.
8. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et-al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
9. Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et-al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034.
10. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et-al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
11. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et-al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
12. Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA-Jr, Donehower RC, et-al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 2013; 119: 4137-4144.
13. Stremitzer S, Stift J, Gruenberger B, Tamandl D, Aschacher T, Wolf B, et-al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg 2012; 99: 1575-1582.
14. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, et-al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258: 619-626.
15. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341.
16. Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, et-al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 2010; 17: 572-578.
17. Russo A, Migliavacca M, Bazan V, Maturi N, Morello V, Dardanoni G, et-al. Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases. Cell Prolif 1998; 31: 139-153.
18. Cejas P, Lopez-Gomez M, Aguayo C, Madero R, de Castro Carpeno J, Belda-Iniesta C, et-al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 2009; 4: e8199.
19. Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, et-al. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 2001; 27: 80-87.
20. Huang CJ, Teng HW, Chien CC, Lin JK, Yang SH,. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer. PLoS One 2013; 8: e65117.
21. Isella C, Mellano A, Galimi F, Petti C, Capussotti L, De Simone M, et-al. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann Surg 2013; 257: 1089-1095.
22. Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK, et-al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 2012; 106: 123-129.
23. Umeda Y, Nagasaka T, Mori Y, Sadamori H, Sun DS, Shinoura S, et-al. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J Hepatobiliary Pancreat Sci 2013; 20: 223-233.
24. Kemeny NE, Chou JF, Capanu M, Gewirtz AN, Cercek A, Kingham TP, et-al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 2014; 120: 3965-3971.
25. Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima A, et-al. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Sci 2014; 105: 1002-1007.
26. Kastrinakis WV, Ramchurren N, Maggard M, Steele G-Jr, Summerhayes IC,. K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 1995; 130: 9-14.
27. Pollock CB, Shirasawa S, Sasazuki T, Kolch W, Dhillon AS,. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res 2005; 65: 1244-1250.
28. Schramm K, Krause K, Bittroff-Leben A, Goldin-Lang P, Thiel E, Kreuser ED,. Activated K-ras is involved in regulation of integrin expression in human colon carcinoma cells. Int J Cancer 2000; 87: 155-164.
29. Serova M, Astorgues-Xerri L, Bieche I, Albert S, Vidaud M, Benhadji KA, et-al. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther 2010; 9: 1308-1317.
30. Keller JW, Franklin JL, Graves-Deal R, Friedman DB, Whitwell CW, Coffey RJ,. Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. J Cell Physiol 2007; 210: 740-749.
31. Makrodouli E, Oikonomou E, Koc M, Andera L, Sasazuki T, Shirasawa S, et-al. BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol Cancer 2011; 10: 118.
32. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS,. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011; 50: 307-312.
33. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Barni S,. KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. Med Oncol 2013; 30: 650.
34. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et-al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
35. Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, et-al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 2010; 17: 1429-1434.
36. Knijn N, Mekenkamp LJ, Klomp M, Vink-Borger ME, Tol J, Teerenstra S, et-al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104: 1020-1026.
37. Tie J, Lipton L, Desai J, Gibbs P, Jorissen RN, Christie M, et-al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 2011; 17: 1122-1130.
38. Oudejans JJ, Slebos RJ, Zoetmulder FA, Mooi WJ, Rodenhuis S,. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 1991; 49: 875-879.
39. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, et-al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30: 2956-2962.
40. Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, et-al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin Cancer Res 2013; 19: 4104-4113.
41. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M,. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014; 53: 852-864.
42. Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et-al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014; 20: 430-435.
43. Netzel BC, Grebe SK,. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer. Clin Chim Acta 2013; 425: 1-2.
44. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, et-al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008; 34: 55-60.
45. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, et-al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 2013; 20: 946-955.
46. Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, et-al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 2007; 246: 806-814.
47. Minagawa M, Yamamoto J, Kosuge T, Matsuyama Y, Miyagawa S, Makuuchi M,. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation. Arch Surg 2007; 142: 269-276.
48. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et-al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996; 77: 1254-1262.
49. Kattan MW, Gonen M, Jarnagin WR, DeMatteo R, D'Angelica M, Weiser M, et-al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008; 247: 282-287.
50. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, et-al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302: 2338-2344.
51. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, et-al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 2012; 30: 4566-4572.
52. Blazer DG-III, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et-al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344-5351.
53. Mise Y, Zimmitti G, Shindoh J, Kopetz S, Loyer EM, Andreou A, et-al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy prior to resection of colorectal liver metastases. Ann Surg Oncol 2015; 22: 834-842.
54. Kawamoto Y, Tsuchihara K, Yoshino T, Ogasawara N, Kojima M, Takahashi M, et-al. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer 2012; 107: 340-344.
55. Søreide K, Sandvik OM, Søreide JA,. KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: a biomarker of cancer biology or a byproduct of patient selection? Cancer 2014; 120: 3862-3865.